Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer

In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform analytical and clinical validation of a KRAS ctDNA assay in a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathology-certified clinical laboratory.Digital-droplet PCR was used to detect the major PDAC-associated somatic KRAS mutations (G12D, G12V,...